FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069901281> ?p ?o ?g. }

• W2069901281 endingPage "772" @default.
• W2069901281 startingPage "767" @default.
• W2069901281 abstract "A phase II study was conducted to evaluate the safety and efficacy of fludarabine, cytarabine (ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) treatment in patients with Richter's syndrome (RS), refractory prolymphocytic leukemia (PLL) or refractory non-Hodgkin's lymphoma (NHL). Twenty-two patients with RS, refractory PLL, or refractory NHL were entered into this trial between March 1997 and February 2001. Median age was 62 years (42-74); 77% were over 60 years of age. Histologic diagnosis was large cell NHL transformation in 15 patients with CLL, immunoblastic transformation of CLL in one, refractory PLL in three, and refractory NHL in three patients. Treatment consisted of fludarabine 30mg/m2 (days 1-3), ara-C 0.5g/m2 (days 3-4), cyclophosphamide 250 mg/m2 (days 2-4), cisplatin 15 mg/m2 IV CI (days 1-4) with GM-CSF 250 microg/m2 from day 5 to recovery of neutrophils and antibiotic prophylaxis. Patients with response were to receive a maximum of six cycles of therapy. Eighteen patients were evaluable for response; one patient achieved a complete remission (5%), 12 stable disease/no response (67%) and five patients had progressive disease (28%). The median survival was 2.2 months (range, 1-19); the median failure-free survival was 1.5 months (range, 0.5-18.6). Grade III/IV toxicities were as follows: anemia in 62% of cycles; leucopoenia in 66%; granulocytopenia in 90%; thrombocytopenia in 83%; hyperbilirubinemia in 14%; hyperuricemia in 17%; hyponatremia in 17%; hypokalemia in 14%; hypophosphatemia in 10%; hypoalbulinemia in 14%; hypocalcemia in 7%; and hypercalcemia in 3%. One (3%) patient developed cardiac failure. Forty-one percent of the cycles were complicated with fever, 34% with non-neutropenic fever, and 55% cycles with infections (fungal 31%; bacterial 57%; HSV 6%; VZV 6%). FACPGM had very limited activity and significant toxicity in a cohort of patients with heavily pretreated refractory lymphoproliferative disorders." @default.
• W2069901281 created "2016-06-24" @default.
• W2069901281 creator A5006104041 @default.
• W2069901281 creator A5015140142 @default.
• W2069901281 creator A5026347795 @default.
• W2069901281 creator A5027575595 @default.
• W2069901281 creator A5044840107 @default.
• W2069901281 creator A5061285204 @default.
• W2069901281 creator A5079262854 @default.
• W2069901281 creator A5090435894 @default.
• W2069901281 date "2002-01-01" @default.
• W2069901281 modified "2023-10-17" @default.
• W2069901281 title "Phase II Study of Fludarabine, Cytarabine (Ara-C), Cyclophosphamide, Cisplatin and GM-CSF (FACPGM) in Patients With Richter's Syndrome or Refractory Lymphoproliferative Disorders" @default.
• W2069901281 cites W1756818535 @default.
• W2069901281 cites W179748155 @default.
• W2069901281 cites W1939358691 @default.
• W2069901281 cites W2011485783 @default.
• W2069901281 cites W2041795664 @default.
• W2069901281 cites W2061000716 @default.
• W2069901281 cites W2079196783 @default.
• W2069901281 cites W2079546047 @default.
• W2069901281 cites W2110360539 @default.
• W2069901281 cites W2115298530 @default.
• W2069901281 cites W2129869923 @default.
• W2069901281 cites W2135368384 @default.
• W2069901281 cites W2164831445 @default.
• W2069901281 cites W2167499476 @default.
• W2069901281 cites W2220686306 @default.
• W2069901281 cites W2221772045 @default.
• W2069901281 cites W2294516256 @default.
• W2069901281 cites W2337660074 @default.
• W2069901281 cites W2389429 @default.
• W2069901281 cites W4246675764 @default.
• W2069901281 cites W56723042 @default.
• W2069901281 cites W1967477724 @default.
• W2069901281 doi "https://doi.org/10.1080/10428190290016872" @default.
• W2069901281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12153163" @default.
• W2069901281 hasPublicationYear "2002" @default.
• W2069901281 type Work @default.
• W2069901281 sameAs 2069901281 @default.
• W2069901281 citedByCount "56" @default.
• W2069901281 countsByYear W20699012812012 @default.
• W2069901281 countsByYear W20699012812013 @default.
• W2069901281 countsByYear W20699012812014 @default.
• W2069901281 countsByYear W20699012812015 @default.
• W2069901281 countsByYear W20699012812016 @default.
• W2069901281 countsByYear W20699012812017 @default.
• W2069901281 countsByYear W20699012812018 @default.
• W2069901281 countsByYear W20699012812019 @default.
• W2069901281 countsByYear W20699012812020 @default.
• W2069901281 countsByYear W20699012812021 @default.
• W2069901281 countsByYear W20699012812022 @default.
• W2069901281 countsByYear W20699012812023 @default.
• W2069901281 crossrefType "journal-article" @default.
• W2069901281 hasAuthorship W2069901281A5006104041 @default.
• W2069901281 hasAuthorship W2069901281A5015140142 @default.
• W2069901281 hasAuthorship W2069901281A5026347795 @default.
• W2069901281 hasAuthorship W2069901281A5027575595 @default.
• W2069901281 hasAuthorship W2069901281A5044840107 @default.
• W2069901281 hasAuthorship W2069901281A5061285204 @default.
• W2069901281 hasAuthorship W2069901281A5079262854 @default.
• W2069901281 hasAuthorship W2069901281A5090435894 @default.
• W2069901281 hasConcept C121332964 @default.
• W2069901281 hasConcept C126322002 @default.
• W2069901281 hasConcept C141071460 @default.
• W2069901281 hasConcept C142424586 @default.
• W2069901281 hasConcept C2775983024 @default.
• W2069901281 hasConcept C2776694085 @default.
• W2069901281 hasConcept C2776755627 @default.
• W2069901281 hasConcept C2777938653 @default.
• W2069901281 hasConcept C2778041864 @default.
• W2069901281 hasConcept C2778461978 @default.
• W2069901281 hasConcept C2779263901 @default.
• W2069901281 hasConcept C71924100 @default.
• W2069901281 hasConcept C87355193 @default.
• W2069901281 hasConcept C90924648 @default.
• W2069901281 hasConceptScore W2069901281C121332964 @default.
• W2069901281 hasConceptScore W2069901281C126322002 @default.
• W2069901281 hasConceptScore W2069901281C141071460 @default.
• W2069901281 hasConceptScore W2069901281C142424586 @default.
• W2069901281 hasConceptScore W2069901281C2775983024 @default.
• W2069901281 hasConceptScore W2069901281C2776694085 @default.
• W2069901281 hasConceptScore W2069901281C2776755627 @default.
• W2069901281 hasConceptScore W2069901281C2777938653 @default.
• W2069901281 hasConceptScore W2069901281C2778041864 @default.
• W2069901281 hasConceptScore W2069901281C2778461978 @default.
• W2069901281 hasConceptScore W2069901281C2779263901 @default.
• W2069901281 hasConceptScore W2069901281C71924100 @default.
• W2069901281 hasConceptScore W2069901281C87355193 @default.
• W2069901281 hasConceptScore W2069901281C90924648 @default.
• W2069901281 hasIssue "4" @default.
• W2069901281 hasLocation W20699012811 @default.
• W2069901281 hasLocation W20699012812 @default.
• W2069901281 hasOpenAccess W2069901281 @default.
• W2069901281 hasPrimaryLocation W20699012811 @default.
• W2069901281 hasRelatedWork W2357984488 @default.
• W2069901281 hasRelatedWork W2358739720 @default.
• W2069901281 hasRelatedWork W2368167615 @default.

• next